Orelabrutinib clinical trials
Also written ICP-022.
How each study uses orelabrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the orelabrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
94 studies that test it; most in 2026 (16)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 14 |
| 2022 | 12 |
| 2023 | 12 |
| 2024 | 14 |
| 2025 | 15 |
| 2026 | 16 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 68
Beijing InnoCare Pharma Tech Co., Ltd. (22) · Ruijin Hospital (11) · The First Affiliated Hospital with Nanjing Medical University (7) · Peking Union Medical College Hospital (5) · Sun Yat-sen University (4) · The First Affiliated Hospital of Soochow University (4) · Second Affiliated Hospital, School of Medicine, Zhejiang University (4) · Institute of Hematology & Blood Diseases Hospital, China (3)
Often tested with
Tested in the same studies.
R-CHOP Regimen (4) · Lenalidomide (3) · Pola-R-CHP Regimen (3) · Zuberitamab (2) · Rituximab (2) · Polatuzumab vedotin (2) · Venetoclax (2) · Obinutuzumab (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Orelabrutinib is the comparator. A study of two new drugs counts under both.
- 1Rocbrutinib · Guangzhou Lupeng Pharmaceutical Company LTD. · next primary completion May 2031
Reaching primary completion within a year · 13, 2 in phase 3
Studies that test orelabrutinib, phase 3 first.
- Apr 2027High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaPhase 3 · Shandong University
- Jul 2027Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentPhase 3 · Ruijin Hospital
- Nov 2026Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL PatientsPhase 2 · Ruijin Hospital
- Nov 2026Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)Phase 2 · Sun Yat-sen University
- Dec 2026A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaPhase 2 · Ruijin Hospital
- Dec 2026Clinical Study of OR for Second-line Treatment of Refractory MZLPhase 4 · Lixia Sheng
- Jun 2027Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone LymphomasPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Jun 2027Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local TherapyNot applicable · The First Affiliated Hospital of Xiamen University
- Jul 2027Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)Phase 2 · First Affiliated Hospital of Zhejiang University
- Sep 2027A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA)Not applicable · Ruijin Hospital
Studies
Open first, then newest update. How each study uses orelabrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 94
- Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07938619Written as Orelabrutinib
- A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisRecruitingPhase 3Zenas BioPharma (USA), LLCNCT07299019Written as Orelabrutinib
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRecruitingPhase 3Zenas BioPharma (USA), LLCNCT07067463Written as Orelabrutinib
- Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)Not yet recruitingPhase 1Liu QingNCT07875972Written as Orelabrutinib
- Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCLRecruitingNot applicableThe First Affiliated Hospital of Xiamen UniversityNCT07778212Written as Orelabrutinib Combined with Pola-R-CHP Regimen
- Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSLRecruitingPhase 2/3Huashan HospitalNCT07185373Written as Orelabrutinib
- Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingPhase 2Ruijin HospitalNCT07272499Written as Orelabrutinib
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingPhase 3Ruijin HospitalNCT07719855Written as Orelabrutinib
- Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07719556Written as Orelabrutinib
- Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell LymphomaNot yet recruitingPhase 2Ou Bai, MD/PHDNCT07677813Written as R-CHOP+Orelabrutinib
- A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07585747Written as Orelabrutinib
- Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaRecruitingPhase 2Zhejiang Cancer HospitalNCT07554898Written as Orelabrutinib
- High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaRecruitingPhase 3Shandong UniversityNCT07559331Written as High-Dose Dexamethasone Combined with Orelabrutinib
- Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)RecruitingPhase 2Sun Yat-sen UniversityNCT04989621Written as Orelabrutinib and Rituximab
- Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07499271Written as Orelabrutinib
- MZL-IPI Risk-adapted Targeted Therapy in Untreated MZLRecruitingPhase 2Ruijin HospitalNCT06793189Written as Obinutuzumab and Orelabrutinib
- Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07448324Written as Orelabrutinib
- Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07441993Written as Orelabrutinib
- Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)RecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06504940Written as Orelabrutinib combined with bendamustine and rituximab
- PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.RecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07410520Written as Orelabrutinib
See all 94 studies that test orelabrutinib →
Given beside what is tested · 4 — orelabrutinib is usual care or a partner of the new treatment
- Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaNot yet recruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT07896590Written as Orelabrutinib
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT07784101Written as Orelabrutinib
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingPhase 2/3Beijing InnoCare Pharma Tech Co., Ltd.NCT06378138Written as Orelabrutinib
- Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaActive, not recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07247383Written as Orelabrutinib (ICP-022)
As the comparator · 1 — what is tested is compared with orelabrutinib
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
Codes
What other systems call orelabrutinib · ClinicalTrials.gg INT002046
- MeSH (NLM) C000729508orelabrutinibOne source ClinicalTrials.gov
- UNII (FDA) WJA5UO9E10ORELABRUTINIBConfirmed FDA, Wikidata
- Wikidata Q126122244orelabrutinibConfirmed FDA, Wikidata
- NCI Thesaurus C156173OrelabrutinibOne source FDA
- DrugBank DB16272One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729508 | orelabrutinib | One source ClinicalTrials.gov |
| UNII (FDA) | WJA5UO9E10 | ORELABRUTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q126122244 | orelabrutinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C156173 | Orelabrutinib | One source FDA |
| DrugBank | DB16272 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.